Advertisement

Topics

Acute Lung Injury - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Acute Lung Injury - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 106-page report is available in PDF from $2000.

Acute Lung Injury - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Acute Lung Injury - Pipeline Review, H1 2015’, provides an overview of the Acute Lung Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Lung Injury Overview 10
Therapeutics Development 11
Pipeline Products for Acute Lung Injury - Overview 11
Pipeline Products for Acute Lung Injury - Comparative Analysis 12
Acute Lung Injury - Therapeutics under Development by Companies 13
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 16
Acute Lung Injury - Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Acute Lung Injury - Products under Development by Companies 20
Acute Lung Injury - Products under Investigation by Universities/Institutes 22
Acute Lung Injury - Companies Involved in Therapeutics Development 23
Altor BioScience Corporation 23
Apeptico Forschung und Entwicklung GmbH 24
BioMarck Pharmaceuticals, Ltd. 25
Carolus Therapeutics, Inc. 26
CompleGen, Inc. 27
FirstString Research, Inc. 28
GlaxoSmithKline Plc 29
Histocell S.L. 30
Navigen Pharmaceuticals, Inc. 31
Noxxon Pharma AG 32
S-Evans Biosciences, Inc. 33
Silence Therapeutics Plc 34
Stemedica Cell Technologies, Inc. 35
Therametrics holding AG 36
Xiber Science GmbH 37
Acute Lung Injury - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
ALT-836 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AP-301 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Atu-111 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Atu-112 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BC-1215 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BIO-10901 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CGX-1037 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CT-2009 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DasKloster-0141-01 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DasKloster-1000–04 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress…

For more information open Acute Lung Injury - Pipeline Review, H1 2015.

SKU: GMDHC6701IDB

Original Article: Acute Lung Injury - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Acute Lung Injury - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...